Regulatory Storm Hits Hims & Hers as FDA Targets Marketing Claims

Aggressive Marketing Draws Regulatory Scrutiny

Shares of telehealth provider Hims & Hers Health faced significant pressure this week following a regulatory confrontation with the U.S. Food and Drug Administration. The agency issued a formal warning letter concerning the company’s advertising practices for its compounded weight loss medications, sending the stock downward and raising serious questions about its core business strategy.

The FDA’s communication, dated September 9, took specific issue with how Hims & Hers promoted its semaglutid-based products. These compounded formulations mimic the active ingredient found in branded drugs like Ozempic and Wegovy. Regulators flagged claims such as “same active ingredient as Ozempic and Wegovy” and “clinically proven ingredients” as being “false or misleading.”